Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial - Bishop, Nick; Adami, Silvano; Ahmed, S Faisal; Antón, Jordi; Arundel, Paul; Burren, Christine P; Devogelaer, Jean-Pierre; Hangartner, Thomas; Hosszú, Eva; Lane, Joseph M; Lorenc, Roman; Mäkitie, Outi; et al. (The Lancet (British edition), 2013)
Keywords: Administration, Oral; Adolescent; Age; Alkaline Phosphatase - metabolism; Analysis of Variance; Biological and medical sciences; Bisphosphonates; Bone density; Bone Density - drug effects; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - adverse effects; Bone diseases; bone formation; Bone mineral density; Child; Child, Preschool; children; Collagen - metabolism; Diseases of the osteoarticular system; Double-Blind Method; Drug Administration Schedule; drugs; Etidronic Acid - administration & dosage; Etidronic Acid - adverse effects; Etidronic Acid - analogs & derivatives; Female; Fractures; General aspects; human resources; Humans; Internal Medicine; intravenous injection; lumbar spine; Male; Malformations and congenital and or hereditary diseases involving bones. Joint deformations; Medical sciences; Older people; oral administration; Osteogenesis Imperfecta - drug therapy; Osteogenesis Imperfecta - physiopathology; Osteoporosis; Pain; patients; Risedronate Sodium; risk; Spine; Treatment Outcome; Human; Antiosteoporotic; Diseases of the osteoarticular system; Antiresorptive agent; Diphosphonic acid derivatives; Bisphosphonates; Randomized controlled trial; Genetic disease; Medicine; Antiosteoclastic agent; Risedronic acid; Double blind study; Osteogenesis imperfecta; Clinical trial; Osteochondrodysplasia; Child